InfinixBio


InfinixBio is a full-service, cost-effective Contract Research Organization (CRO) that partners with clients to expand their capabilities and meet key milestones. Established in 2006, the company operates from Columbus and Athens, Ohio, and is renowned for its innovative and customizable approach to biotechnology solutions. With a team comprising 38% PhDs and over 60 issued and pending patents, InfinixBio excels in drug discovery, pharmacology, and clinical diagnostics, providing comprehensive services from early drug development to clinical trials and regulatory approval.

Infinix Bio

InfinixBio


What We Do

InfinixBio offers services in assay development, protein biochemistry, genetic engineering, and cell line development to advance drug discovery and regulatory approval processes.

Specializing in GLP and non-GLP environments, InfinixBio provides assay development, validation, sample testing, pharmacokinetic and toxicology studies, and biomarker testing.

InfinixBio offers GLP-compliant assay development, validation, and extensive sample testing, excelling in pharmacokinetic studies, toxicology studies, and biomarker testing services.

InfinixBio provides genetic engineering services, including gene design and construction, bacterial and mammalian genome editing, and BioProduction system development.

InfinixBio designs and conducts studies to support 510(k) and Laboratory Developed Tests (LDT) submissions for medical devices and diagnostic tests.


Diagnostics


Key People

Chief Executive Officer

LinkedIn

Chief Scientific Officer

LinkedIn

News & Updates

InfinixBio has appointed Jennifer Logan as the new Chief Marketing Officer to enhance business development and strategic growth.

InfinixBio celebrates a significant milestone in Alzheimer's research, showcasing their commitment to advancing biotechnology.